MedTrace Logo

The Effectiveness of Personalized Colorectal Cancer Screening Based on Fecal Hemoglobin Concentration

NCT05423886 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20000

Last updated 2022-06-21

No results posted yet for this study

Summary

We aim to improve the yield and effectiveness of the Dutch colorectal cancer screening program by using a personalized screening strategy based on fecal Hemoglobin concentration in previous screening round for participants with a negative fecal immunochemical test (FIT).

Conditions

Interventions

OTHER

Personalized screening invitation interval

Time to receive the next invitation for fecal immunochemical testing screening, will depend based on individuals risk determined by fecal Hemoglobin concentration

Sponsors & Collaborators

  • Esther Toes-Zoutendijk

    lead OTHER

Principal Investigators

  • Iris Lansdorp-Vogelaar, PhD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
56 Years
Max Age
71 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05423886 on ClinicalTrials.gov